PMID- 35313370
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20230401
IS  - 1833-3516 (Print)
IS  - 2209-1491 (Electronic)
IS  - 1833-3516 (Linking)
VI  - 52
IP  - 1
DP  - 2022 Mar 31
TI  - Hyperbaric oxygen treatment for refractory haemorrhagic cystitis occurring after 
      chemotherapy and haematopoietic stem cell transplantation: retrospective analysis 
      of 25 patients.
PG  - 27-34
LID - 10.28920/dhm52.1.27-34 [doi]
AB  - INTRODUCTION: Intractable haemorrhagic cystitis (HC) is a serious complication of 
      chemotherapy (CT) and haematopoietic stem cell transplantation (HSCT). Hyperbaric 
      oxygen treatment (HBOT) is a promising treatment option based on the similarities 
      in injury pattern and observed histological changes with radiation induced HC, 
      which is an approved indication. We present our experience with HBOT in HC 
      occurring after CT and HSCT. METHODS: Medical files of patients who underwent 
      HBOT between the years 2000-2020 for HC that developed after chemotherapy and/or 
      HSCT were reviewed. Demographic data, primary diagnosis, history of HC and 
      details of HBOT were documented. Treatment outcomes were grouped as complete and 
      partial healing, no response and deterioration. RESULTS: Twenty-five patients 
      underwent a median of 12 HBOT sessions for HC occurring after CT and HSCT. 
      Complete healing was observed in 11 patients whereas haematuria improved in seven 
      patients. HC grades after HBOT were significantly better than referral grades. A 
      significant correlation was shown with the number of HBOT sessions and change in 
      haematuria. Patients who underwent seven or more HBOT sessions benefitted most. 
      CONCLUSIONS: HBOT appears to be a safe and effective treatment for refractory HC 
      following CT and HSCT. Higher quality evidence would be needed to prove efficacy. 
      However, given the difficulty of conducting randomised controlled trials on such 
      a vulnerable and small group of patients with few treatment options, and given 
      the consistency of current observational evidence, HC occurring after CT and HSCT 
      may be considered as an optional or investigational indication for HBOT.
CI  - Copyright: This article is the copyright of the authors who grant Diving and 
      Hyperbaric Medicine a non-exclusive licence to publish the article in electronic 
      and other forms.
FAU - Ozturk, Handan
AU  - Ozturk H
AD  - Ankara Numune Research and Training Hospital, Underwater and Hyperbaric Medicine 
      Department, Ankara, Turkey.
FAU - Mirasoglu, Bengusu
AU  - Mirasoglu B
AD  - Istanbul University, Istanbul Faculty of Medicine, Underwater and Hyperbaric 
      Medicine Department, Istanbul, Turkey.
AD  - Corresponding author: Associate Professor Bengusu Mirasoglu, Istanbul Tip 
      Fakultesi, Sualti Hekimligi ve Hiperbarik Tip Anabilim Dali, 34093 Fatih, 
      Istanbul, Turkey, bengusu.mirasoglu@istanbul.edu.tr.
FAU - Aktas, Samil
AU  - Aktas S
AD  - Istanbul University, Istanbul Faculty of Medicine, Underwater and Hyperbaric 
      Medicine Department, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Diving Hyperb Med
JT  - Diving and hyperbaric medicine
JID - 101282742
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - *Cystitis/chemically induced/therapy
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - *Hyperbaric Oxygenation/adverse effects
MH  - Oxygen
MH  - Retrospective Studies
PMC - PMC9177434
OTO - NOTNLM
OT  - Cyclophosphamide
OT  - Hematopoietic stem cell transplantation
OT  - Hemorrhagic cystitis
OT  - Hyperbaric research
COIS- Conflict of interest and funding: nil
EDAT- 2022/03/22 06:00
MHDA- 2022/03/24 06:00
PMCR- 2023/03/31
CRDT- 2022/03/21 20:13
PHST- 2021/03/09 00:00 [received]
PHST- 2021/12/20 00:00 [accepted]
PHST- 2022/03/21 20:13 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2023/03/31 00:00 [pmc-release]
AID - 10.28920/dhm52.1.27-34 [doi]
PST - ppublish
SO  - Diving Hyperb Med. 2022 Mar 31;52(1):27-34. doi: 10.28920/dhm52.1.27-34.